cardiovascular disease News
-
Shockwave Medical to Participate in Two Upcoming Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences: The 2022 Wells Fargo Healthcare Conference Fireside Chat on Thursday, September 8, 2022, at 9:45 a.m. Eastern Time. The Morgan Stanley ...
-
Correcting and Replacing: Shockwave Medical to Participate in Two Upcoming Investor Conferences
In a release issued under the same headline on August 26, 2022, by Shockwave Medical, Inc. (NASDAQ: SWAV), please note that the fireside chat time for the Wells Fargo Healthcare Conference has been updated. The correct presentation time is 9:10 am Eastern Time. The details for the Morgan Stanley Healthcare Conference remain the same. The corrected release appears below: Shockwave Medical, Inc. ...
-
Genome Biologics Enters Into a Research Collaboration and Exclusive License Option Agreement with Leading Biopharmaceutical Company
Genome Biologics UG, Frankfurt, Germany, today announced that they have entered into a research collaboration with AstraZeneca related to screening of proteins of the human secretome able to drive cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxicity (CT). Cardiovascular disease (CVD) remains the leading cause of death and disability globally, ...
-
Visit Aktiedagen Lund September 26, and learn how ultrasound can be used to fight the world’s deadliest diseases
At Aktiedagen Lund on Monday 26 September 2022, AcouSort’s Commercial Director Agnes Michanek will talk about how AcouSort’s unique and validated ultrasound technology can be used in the fight against cardiovascular diseases, infections, and cancer – the three deadliest diseases in the world. AcouSort is at a very exciting stage in the company’s development with a growing ...
By AcouSort AB
-
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally
Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development. Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of ...
-
Online clinic Medon collaborates with Longenesis to develop a cardiovascular disease risk calculator
In order to increase the public awareness of cardiovascular health and encourage the population to take preventive action by identifying and mitigating the effects of cardiovascular disease (CVD) risk factors in a timely fashion, the online clinic Medon in collaboration with the health technology start-up Longenesis, has published a survey to determine the CVD risk. After filling the survey, each ...
By Longenesis
-
Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
Hanover, Germany, March 29, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 ...
-
COVID-19 Statement From Reflow Medical
Reflow Medical is taking steps to prevent the community spread of COVID-19 and to ensure the safety of our employees. We are adapting to the changing environment as we continue to design and develop medical devices used in life-saving treatments for cardiovascular disease. We want to express our gratitude to those in the healthcare community, including our clinical partners, who are serving ...
-
EPA holds seminar on air pollution and cardiovascular disease
The U.S. Environmental Protection Agency is sponsoring a seminar called “Breathe Cleaner, Live Longer: Understanding Air Pollution after 40 Years.” The event is co-sponsored by the American Heart Association and the U.S. House of Representatives Committee on Science and Technology. World-renowned scientific experts will discuss the impacts of air pollution on life expectancy and ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with ...
-
Cardior`s pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal
Hanover, Germany, February 9, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from ...
-
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart
Hanover, Germany, June 24, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of ...
-
Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
Hanover, Germany, November 12, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today positive results of a Phase Ib study with its lead compound CDR132L. The compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Tudorza®’s supplemental New Drug Application (sNDA) for the inclusion of unique new clinical data in the product’s ...
-
Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
Hanover, Germany, July 13, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy and heart failure. Results were ...
-
Cardior Pharmaceuticals ´ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Mode
Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac ...
-
CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership
CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support of CathWorks’ fast-growing install-base of customers globally. CathWorks ...
By CathWorks
-
CathWorks FFRangio System outcomes study to be presented at ACC 2022
CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC. Dr. Witberg and his co-investigators in Israel and Japan examined the 1-year clinical outcomes of ...
By CathWorks
-
Diesel Exhaust + Cholesterol = Cardiovascular Disease
LOS ANGELES, California, July 26, 2007 (ENS) - Exposure to a combination of diesel exhaust and high blood cholesterol increases the risk for heart attack and stroke far more than exposure to either factor alone, new research reveals. The results indicate that controlling air pollution may prove to be a powerful tool for preventing cardiovascular disease. Published in today's edition of the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you